Tokyo Tape
Sign in
← BrightPath Biotherapeutics

Annual report

4594.TEDINET S100VZBU
Period2024-04-01 → 2025-03-31
Filed2025-06-19
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥1m2024-04-01 → 2025-03-31StandaloneNet sales
Revenue¥72,0002023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥5m2022-04-01 → 2023-03-31dStandaloneNet sales (5-year summary)
Revenue¥15m2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥3m2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Operating income−¥1.2bn2024-04-01 → 2025-03-31StandaloneOperating income
Operating income−¥1.2bn2023-04-01 → 2024-03-31StandaloneOperating income
Ordinary income−¥1.1bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income−¥1.2bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income−¥1.5bn2022-04-01 → 2023-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.5bn2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.7bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.1bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Profit before tax−¥1.2bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Net income−¥1.2bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income−¥1.2bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income−¥1.5bn2022-04-01 → 2023-03-31dStandaloneNet income loss (5-year summary)
Net income−¥1.5bn2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income−¥1.7bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Total assets¥1.1bnat 2025-03-31StandaloneAssets
Total assets¥1.2bnat 2024-03-31StandaloneAssets
Total assets¥1.7bnat 2023-03-31dStandaloneTotal assets (5-year summary)
Total assets¥2.8bnat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥3.7bnat 2021-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥196mat 2025-03-31StandaloneLiabilities
Total liabilities¥251mat 2024-03-31StandaloneLiabilities
Net assets / equity¥925mat 2025-03-31StandaloneNet assets
Net assets / equity¥979mat 2024-03-31StandaloneNet assets
Net assets / equity¥1.6bnat 2023-03-31dStandaloneNet assets
Net assets / equity¥2.5bnat 2022-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥3.5bnat 2021-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥810mat 2025-03-31StandaloneCash and deposits
Cash and deposits¥1.1bnat 2024-03-31StandaloneCash and deposits
Cash & equivalents¥810mat 2025-03-31StandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2024-03-31StandaloneCash and cash equivalents
Cash & equivalents¥1.5bnat 2023-03-31dStandaloneCash and cash equivalents
Cash & equivalents¥2.3bnat 2022-03-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥3.3bnat 2021-03-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.3bn2024-04-01 → 2025-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2023-04-01 → 2024-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2022-04-01 → 2023-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.5bn2021-04-01 → 2022-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.8bn2020-04-01 → 2021-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥1m2024-04-01 → 2025-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥8m2023-04-01 → 2024-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥2m2022-04-01 → 2023-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥18m2021-04-01 → 2022-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥36m2020-04-01 → 2021-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.0bn2024-04-01 → 2025-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥691m2023-04-01 → 2024-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥432m2022-04-01 → 2023-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥569m2021-04-01 → 2022-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.1bn2020-04-01 → 2021-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-14.122024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-18.212023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-24.92022-04-01 → 2023-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.552021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.142020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥9.98at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥13.52at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥24.6at 2023-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥45.4at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥69.1at 2021-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio80.6%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio77.7%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio90.9%at 2023-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.5%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio93.7%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued90,491,300at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued70,741,300at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued62,891,200at 2023-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued55,253,100at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued50,817,500at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees24at 2025-03-31StandaloneNumber of employees
Employees24at 2024-03-31StandaloneNumber of employees
Employees32at 2023-03-31dStandaloneNumber of employees
Employees38at 2022-03-31dStandaloneNumber of employees
Employees44at 2021-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 742
ItemContextValueUnit
Redemption of bonds fin cfCurrentYearDuration_NonConsolidatedMember-587500000JPY
Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cfPrior1YearDuration_NonConsolidatedMember573382000JPY
Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cfCurrentYearDuration_NonConsolidatedMember1090805000JPY
Purchase of treasury stock fin cfPrior1YearDuration_NonConsolidatedMember－JPY
Purchase of treasury stock fin cfCurrentYearDuration_NonConsolidatedMember-2000JPY
Proceeds from issuance of subscription rights to shares fin cfPrior1YearDuration_NonConsolidatedMember5076000JPY
Proceeds from issuance of subscription rights to shares fin cfCurrentYearDuration_NonConsolidatedMember2580000JPY
Payments for purchase of treasury subscription right to share fin cfPrior1YearDuration_NonConsolidatedMember－JPY
Payments for purchase of treasury subscription right to share fin cfCurrentYearDuration_NonConsolidatedMember-1042000JPY
Net cash provided by used in financing activitiesPrior1YearDuration_NonConsolidatedMember690959000JPY
Net cash provided by used in financing activitiesCurrentYearDuration_NonConsolidatedMember1004840000JPY
Net increase decrease in cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember-473609000JPY
Net increase decrease in cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember-246889000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember1530969000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember1057360000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember1057360000JPY
Cash and cash equivalentsCurrentYearInstant_NonConsolidatedMember810470000JPY
Accumulated depreciation ppe by groupPrior1YearInstant_NonConsolidatedMember-390241000JPY
Accumulated depreciation ppe by groupCurrentYearInstant_NonConsolidatedMember-389388000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodPrior1YearDuration_NonConsolidatedMember775556000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodCurrentYearDuration_NonConsolidatedMember888064000JPY
Directors compensations sgaPrior1YearDuration_NonConsolidatedMember76300000JPY
Directors compensations sgaCurrentYearDuration_NonConsolidatedMember82300000JPY
Salaries and allowances sgaPrior1YearDuration_NonConsolidatedMember29794000JPY
Salaries and allowances sgaCurrentYearDuration_NonConsolidatedMember18485000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember545000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember490000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember48000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember－JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember775556000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember888064000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2025-06-19
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第22期(自　2024年４月１日　至　2025年３月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)ブライトパス・バイオ株式会社
Company name in english cover pageFilingDateInstantBrightPath Biotherapeutics Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　永井 健一
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番22号
Telephone number address of registered headquarter cover pageFilingDateInstant044-440-3939
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)管理部　藤井　厚裕
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都千代田区麹町二丁目２番地４
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03-5840-7697(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)管理部　藤井　厚裕
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE31851
Fund codeFilingDateInstant－
Security codeFilingDateInstant45940
Filer name in japaneseFilingDateInstant
Original text (Japanese)ブライトパス・バイオ株式会社

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2024-03-31pass
balance sheet identitynon_consolidated 2025-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · operating cash flownon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flownon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass